| Literature DB >> 23533158 |
Yaso Emmanuel1, Lowri E Cochlin, Damian J Tyler, Celeste A de Jager, A David Smith, Kieran Clarke.
Abstract
Neuronal glucose uptake was thought to be independent of insulin, being facilitated by glucose transporters GLUT1 and GLUT3, which do not require insulin signaling. However, it is now known that components of the insulin-mediated glucose uptake pathway, including neuronal insulin synthesis and the insulin-dependent glucose transporter GLUT4, are present in brain tissue, particularly in the hippocampus. There is considerable recent evidence that insulin signaling is crucial to optimal hippocampal function. The physiological basis, however, is not clear. We propose that while noninsulin-dependent GLUT1 and GLUT3 transport is adequate for resting needs, the surge in energy use during sustained cognitive activity requires the additional induction of insulin-signaled GLUT4 transport. We studied hippocampal high-energy phosphate metabolism in eight healthy volunteers, using a lipid infusion protocol to inhibit insulin signaling. Contrary to conventional wisdom, it is now known that free fatty acids do cross the blood-brain barrier in significant amounts. Energy metabolism within the hippocampus was assessed during standardized cognitive activity. (31)Phosphorus magnetic resonance spectroscopy was used to determine the phosphocreatine (PCr)-to-adenosine triphosphate (ATP) ratio. This ratio reflects cellular energy production in relation to concurrent cellular energy expenditure. With lipid infusion, the ratio was significantly reduced during cognitive activity (PCr/ATP 1.0 ± 0.4 compared with 1.4 ± 0.4 before infusion, P = 0.01). Without lipid infusion, there was no reduction in the ratio during cognitive activity (PCr/ATP 1.5 ± 0.3 compared with 1.4 ± 0.4, P = 0.57). This provides supporting evidence for a physiological role for insulin signaling in facilitating increased neuronal glucose uptake during sustained cognitive activity. Loss of this response, as may occur in type 2 diabetes, would lead to insufficient neuronal energy availability during cognitive activity.Entities:
Keywords: Brain glucose uptake; diabetes; insulin signaling; neurometabolic coupling
Year: 2013 PMID: 23533158 PMCID: PMC3607154 DOI: 10.1002/brb3.124
Source DB: PubMed Journal: Brain Behav Impact factor: 2.708
Figure 1Timeline to show sequence and timing of blood sampling, cognitive testing, and scanning during each study visit.
Subject characteristics
| Cognitive activity ( | Resting studies ( | |
|---|---|---|
| Age (years) | 25 ± 8 | 20 ± 0 |
| Gender (M:F) | 6:2 | 2:2 |
| BMI (kg/m2) | 23 ± 3 | 21 ± 2 |
Data expressed as mean ± SD. M, male; F, female; BMI, body mass index.
Blood results
| Lipid infusion | Without lipid infusion | |||||||
|---|---|---|---|---|---|---|---|---|
| Glucose (mmol/L) | Insulin (mU/L) | FFA (mmol/L) | B-OHB (mmol/L) | Glucose (mmol/L) | Insulin (mU/L) | FFA (mmol/L) | B-OHB (mmol/L) | |
| Baseline | 3.6 ± 0.4 | 0.21 ± 0.08 | 0.3 ± 0.2 | 0.39 ± 0.03 | 3.5 ± 0.3 | 0.23 ± 0.07 | 0.3 ± 0.1 | 0.38 ± 0.03 |
| 3 h | 3.5 ± 0.2 | 0.23 ± 0.11 | 1.3 ± 0.3 | 0.64 ± 0.11 | 3.4 ± 0.3 | 0.17 ± 0.09 | 0.1 ± 0.1 | 0.37 ± 0.02 |
| 4 h | 3.3 ± 0.3 | 0.21 ± 0.09 | 1.2 ± 0.4 | 0.70 ± 0.15 | 3.4 ± 0.3 | 0.15 ± 0.09 | 0.05 ± 0.05 | 0.36 ± 0.01 |
Data expressed as mean ± SD. Blood results for studies performed both with cognitive testing and resting studies, n = 11. B-OHB = β-hydroxybutyrate.
P < 0.001 versus baseline;
P < 0.0001 versus baseline.
Cognitive test scores
| (max score) | HVLT immediate ( | HVLT delayed ( | HVLT DI | Digit span forward | Digit span backward | Doors |
|---|---|---|---|---|---|---|
| Baseline without infusion | 30 ± 4 | 11 ± 1 | 0 ± 0 | 8 ± 1 | 6 ± 1 | 10 ± 2 |
| Post without infusion | 29 ± 4 | 8 ± 4 | 0 ± 1 | 7 ± 1 | 6 ± 1 | 11 ± 1 |
| Pre lipid infusion | 28 ± 4 | 10 ± 2 | 0 ± 1 | 7 ± 2 | 6 ± 1 | 10 ± 2 |
| Post lipid infusion | 29 ± 2 | 9 ± 2 | −1 ± 1 | 8 ± 1 | 5 ± 1 | 11 ± 1 |
| Paragraph recall imm ( | Paragraph recall del ( | Paragraph recall cued | Trails A (sec) | Trails B (sec) | Trails B–A (sec) | |
| Baseline without infusion | 13 ± 2 | 10 ± 2 | 1 ± 1 | 20 ± 7 | 42 ± 21 | 22 ± 14 |
| Post without infusion | 13 ± 3 | 12 ± 4 | 1 ± 1 | 16 ± 3 | 32 ± 8 | 16 ± 5 |
| Pre lipid infusion | 12 ± 2 | 9 ± 3 | 1 ± 1 | 23 ± 10 | 55 ± 22 | 34 ± 21 |
| Post lipid infusion | 9 ± 4 | 8 ± 3 | 1 ± 1 | 18 ± 6 | 45 ± 26 | 27 ± 21 |
| Dual tasks | STROOP CW ( | STROOP CW int ( | Pattern comp | Letter comp | ||
| Baseline without infusion | 3.3 ± 1.7 | 112 ± 0 | 112 ± 1 | 17 ± 4 | 12 ± 2 | |
| Post without infusion | 2.5 ± 1.7 | 112 ± 0 | 111 ± 1 | 20 ± 2 | 11 ± 2 | |
| Pre lipid infusion | 2.6 ± 2.3 | 112 ± 1 | 111 ± 1 | 17 ± 3 | 10 ± 2 | |
| Post lipid infusion | 1.2 ± 1.3 | 111 ± 2 | 109 ± 2 | 18 ± 4 | 9 ± 2 |
Data are expressed as mean ± SD, HVLT, Hopkins Verbal Learning Test; Imm, immediate recall; del, delayed recall; DI, discrimination index; CW, color word; Int, interference; Comp, comparison. Pattern and letter comparison speed score = number correct in 20 seconds.
P = 0.03 vs. baseline, n = 7.
Figure 2PCr/ATP (phosphocreatine-to-adenosine triphosphate) ratios following cognitive activity. Baseline averaged ratio (1.39 ± 0.40) with drop in ratio after lipid infusion (0.98 ± 0.38, P = 0.01 yellow line) but no change following nicotinic acid control study (1.48 ± 0.27, P = 0.57, red line).
PCr/ATP ratios with cognitive activity and at rest
| Average baseline | Postlipid infusion | Post without infusion | |
|---|---|---|---|
| Cognitive activity ( | 1.4 ± 0.4 | 1.0 ± 0.4 ( | 1.5 ± 0.3 ( |
| Resting ( | 1.5 ± 0.3 | 1.5 ± 0.6 ( | 1.3 ± 0.4 ( |
Data are expressed as mean ± SD. PCr/ATP, phosphocreatine-to-adenosine triphosphate.